3650 results for «414»
3650 results
PCR's Got Talent Round 1 - Session 2
19 May 2026 – From EuroPCR 2026
PCR's Got Talent Round 1 - Session 2 offers a diverse collection of studies addressing coronary microvascular dysfunction, atrial fibrillation management, TAVI outcomes, AI applications in imaging, mitral and tricuspid valve interventions, and in-stent restenosis treatment. The session culminates with deliberations and results announcements, reflecting cutting-edge...
How to face resistent hypertension: when pharmacological treatment is not an option
19 May 2026 – From EuroPCR 2026
Focused on resistant hypertension, this session explores interventional options when pharmacological treatments fall short. It discusses urgent intervention indications, complex cases involving renal artery occlusion, and the role of fractional flow reserve (FFR) in managing pan-vascular disease associated with hypertension.
FFR- and IVUS-guided PCI of a long and calcified LAD lesion - LIVE case
19 May 2026 – From EuroPCR 2026
A 71‑year‑old man with hypertension and dyslipidemia presented with CCS class II angina and three‑vessel coronary artery disease. Functional assessment included CT‑derived micro‑FFR, angiography‑based FFR, and stress myocardial scintigraphy. The only hemodynamically significant lesion was a long, calcified lesion of the LAD.
Lesion preparation was performed with...
TAVI procedural complications - Part 3: vascular complications, coronary issues and more
19 May 2026 – From EuroPCR 2026
This session addresses critical procedural complications during TAVI, emphasizing vascular issues, coronary complications, and complex bailout scenarios. Through challenging case examples, it offers insights into the management and anticipation of such complications to optimize patient outcomes.
Identifying problems and solving complex anatomies during TAVI
19 May 2026 – From EuroPCR 2026
A comprehensive session on managing complex anatomies during Transcatheter Aortic Valve Implantation (TAVI), emphasizing risk markers for peri-operative complications and strategies to address difficult anatomical challenges. Real-world cases illustrate practical approaches and key learnings for handling intricate TAVI scenarios.
Innvolution Healthcare reports one-year findings from the ALCHEMY study evaluating Eternia in 1000 patients at EuroPCR 2026
27 May 2026
Four-Year Outcomes from the EVOLUT Low Risk Trial
26 Oct 2023
Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)
Author
5-year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis (Evolut Low Risk)
01 Apr 2025
Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.
Author
Transcatheter vs surgical aortic valve replacement in aortic stenosis patients at low surgical risk: 3-year outcomes from the Evolut Low Risk trial
05 Mar 2023
Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.
Author
Cardiac biomarkers in patients with asymptomatic severe aortic stenosis: primary biomarker analysis from the EARLY TAVR Trial
01 Apr 2025
Elad Asher provides his take on the primary biomarker analysis from the EARLY TAVR Trial presented by Brian R. Lindman at ACC.25 in Chicago.
Author
